Stroke after treatment with bortezomib and dexamethasone in a Chinese patient with extramedullary relapse of multiple myeloma

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 11, 2010, Pages 776-778

  Guo, H F ^a   Su, H L ^a   Mao, J J ^a   Sun, C ^a   Wang, J ^a   Zhou, X ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bortezomib; Multiple myeloma; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; BETA 2 MICROGLOBULIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; MELPHALAN; NEUROPROTECTIVE AGENT; POTENZAGY; PREDNISOLONE; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ABDOMINAL MASS; AGED; ARTICLE; BRAIN INFARCTION; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CASE REPORT; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; HUMAN; HUMAN TISSUE; LIMB WEAKNESS; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMACYTOMA; RECURRENT CANCER; STROKE; TUMOR BIOPSY;

EID: 78649273715     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48776     Document Type: Article

References (13)

1. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 2609-2617. (Pubitemid 36741588)
2. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008; 359: 906-917.
3. Velcade (bortzomib) for Injection (US package insert). Cambridge, MA: Millennium Pharmaceuticals, Inc; 2003.Available online at http://www.fda.gov/ cder/foi/label/2003/0216lbl.pdf Accessed: May 11, 2009.
4. Bejot Y, Catteau A, Caillier M, Rouaud O, Durier J, Marie C, Di Carlo A, Osseby GV, Moreau T, Giroud M. Trends in incidence, risk factors, and survival in symptomatic lacunar stroke in Dijon, France, from 1989 to 2006: a population-based study. Stroke. 2008; 39: 1945-1951.
5. Jackson C, Sudlow C. Are lacunar strokes really different? A systematic review of differences in risk factor profiles between lacunar and nonlacunar infarcts. Stroke. 2005; 36: 891-901.
6. Goz M, Eren MN, Cakir O. Arterial thrombosis and thalidomide. J Thromb Thrombolysis. 2008; 25: 224-226.
7. Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer. Lancet. 1998; 351: 1077-1080.
8. Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc. 2005; 80: 1549-1551.
9. Menon SP, Rajkumar SV, Lacy M, Falco P, Palumbo A. Thromboembolic events with lenalidomide-based therapy for multiple myeloma.Cancer. 2008; 112: 1522-1528.
10. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B. VTD combination therapy with bortezomib- thalidomide -dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia. 2008; 22: 1419-1427. (Pubitemid 352006086)
11. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.Blood. 2005; 106: 3777-3784.
12. Sohn RH, Deming CB, Johns DC, Champion HC, Bian C, Gardner K, Rade JJ. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood. 2005; 105: 3910-3917.
13. Morita R, Hashino S, Shirai S, Fujita N, Onozawa M, Kahata K, Kondo T, Imamura M, Asaka M. Thrombotic microangiopathy after treatment with bortezomib and dexamethsone in a patient with multiple myeloma. Int J Hematol. 2008; 88: 248-250.